Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway

Biochemical Pharmacology

Volumn 77, Issue 8, 2009, Pages 1328-1336

  Park, Soo Jung ^a,b,c   Kim, Mi Ju ^a   Kim, Hak Bong ^a   Sohn, Hee Young ^b   Bae, Jae Ho ^a   Kang, Chi Dug ^a   Kim, Sun Hee ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Apoptosis; c FLIPL; EGFR; TRAIL; Trichostatin A

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BID; SMALL INTERFERING RNA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DEPHOSPHORYLATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 8; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 62549102884     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.12.027     Document Type: Article

References (42)

1. Baetu T.M., and Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13 (2002) 199-207
2. Nagane M., Huang H.J., and Cavenee W.K. The potential of TRAIL for cancer chemotherapy. Apoptosis 6 (2001) 191-197
3. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10 (2003) 66-75
4. Bhojani M.S., Rossu B.D., and Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther 2 (2003) S71-S78
5. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 39 (2003) 615-647
6. Zhang L., and Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12 (2005) 228-237
7. Safa A.R., Day T.W., and Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8 (2008) 37-46
8. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 94 (2004) 107-114
9. Jin C.Y., Moon D.O., Lee J.D., Heo M.S., Choi Y.H., Lee C.M., et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis 28 (2007) 1058-1066
10. Bonavida B., Ng C.P., Jazirehi A., Schiller G., and Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 15 (1999) 793-802
11. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
12. Watanabe K., Okamoto K., and Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12 (2005) 10-18
13. Vanhaecke T., Henkens T., Kass G.E., and Rogiers V. Effect of the histone deacetylase inhibitor trichostatin A on spontaneous apoptosis in various types of adult rat hepatocyte cultures. Biochem Pharmacol 68 (2004) 753-760
14. Hajji N., Wallenborg K., Vlachos P., Nyman U., Hermanson O., and Joseph B. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogenesis (2007)
15. Ranganathan P., and Rangnekar V.M. Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biol Ther 4 (2005) 391-392
16. Alper O., Bergmann-Leitner E.S., Bennett T.A., Hacker N.F., Stromberg K., and Stetler-Stevenson W.G. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93 (2001) 1375-1384
17. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284 (2003) 31-53
18. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
19. Kitagawa Y., Ueda M., Ando N., Ozawa S., Shimizu N., and Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2 (1996) 909-914
20. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
21. Shrader M., Pino M.S., Lashinger L., Bar-Eli M., Adam L., Dinney C.P., et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 67 (2007) 1430-1435
22. Magne N., Fischel J.L., Tiffon C., Formento P., Dubreuil A., Renee N., et al. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89 (2003) 585-592
23. Zinner R.G., Fossella F.V., Gladish G.W., Glisson B.S., Blumenschein Jr. G.R., Papadimitrakopoulou V.A., et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104 (2005) 2449-2456
24. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
25. Piechocki M.P., Yoo G.H., Dibbley S.K., Amjad E.H., and Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer 119 (2006) 441-454
26. Bremer E., Samplonius D.F., van Genne L., Dijkstra M.H., Kroesen B.J., de Leij L.F., et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280 (2005) 10025-10033
27. Dimanche-Boitrel M.T., Pelletier H., Genne P., Petit J.M., Le Grimellec C., Canal P., et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer 50 (1992) 677-682
28. Park S.J., Wu C.H., and Safa A.R. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways. Anticancer Res 24 (2004) 123-131
29. Debatin K.M., Poncet D., and Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogenesis 21 (2002) 8786-8803
30. Yang Y.L., and Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10 (2000) 169-177
31. Lafky J.M., Wilken J.A., Baron A.T., and Maihle N.J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785 (2008) 232-265
32. Maihle N.J., Baron A.T., Barrette B.A., Boardman C.H., Christensen T.A., Cora E.M., et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 107 (2002) 247-258
33. Panka D.J., Mano T., Suhara T., and Walsh K. Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 (2001) 6893-6896
34. Wang W., Prince C.Z., Mou Y., and Pollman M.J. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 277 (2002) 21723-21729
35. Vanoosten R.L., Moore J.M., Ludwig A.T., and Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 11 (2005) 542-552
36. Gomez-Benito M., Martinez-Lorenzo M.J., Anel A., Marzo I., and Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 313 (2007) 2378-2388
37. Remacle-Bonnet M., Garrouste F., Baillat G., Andre F., Marvaldi J., and Pommier G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 167 (2005) 761-773
38. Psahoulia F.H., Drosopoulos K.G., Doubravska L., Andera L., and Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 6 (2007) 2591-2599
39. Kim Y., Suh N., Sporn M., and Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277 (2002) 22320-22329
40. Li H., Wang X., Li N., Qiu J., and Zhang Y. Cao X. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem 282 (2007) 4943-4950
41. Bortul R., Tazzari P.L., Cappellini A., Tabellini G., Billi A.M., Bareggi R., et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 17 (2003) 379-389
42. Kang Y.C., Kim K.M., Lee K.S., Namkoong S., Lee S.J., Han J.A., et al. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11 (2004) 1287-1298